10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has ...

10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has ...

Regulatory milestone enables commercial expansion into high-need international market10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Em ...

Regulatory milestone enables commercial expansion into high-need international market10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Emi ...

Core Viewpoint - Biomerica, Inc. will implement a 1-for-8 reverse stock split to increase the bid price of its common stock and regain compliance with Nasdaq's minimum bid price requirement [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern time on April 21, 2025, with trading on a split-adjusted basis starting the same day [1]. - The number of shares outstanding will decrease from approximately 20,366,095 shares to about 2,545,762 shares, while the number of authorized shares will remain unchanged [3]. - Stockholders will automatically have fractional shares rounded up to the next whole share, and adjustments will be made to equity awards and option exercise prices accordingly [3][4]. Group 2: Compliance and Authorization - The reverse stock split was authorized by Biomerica's stockholders during the 2024 Annual Meeting held on December 13, 2024, with the final ratio determined by the Board of Directors [2]. - The company aims to enhance its stock price to meet Nasdaq's listing requirements, which is critical for its continued presence on the exchange [2]. Group 3: Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for medical conditions, particularly gastrointestinal and inflammatory diseases [6]. - The company markets products designed to improve health outcomes while reducing healthcare costs, with a strong emphasis on point-of-care testing [6].

Total Revenue Increases 10% Year-Over-YearDelivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2025 ended February 28, 2025. Key Highlights: 1. Fortel® PSA Screening Test Approved by UAE Ministry of Health & Prevention:B ...

Financial Performance - Consolidated net sales for the three months ended February 28, 2025, were approximately $1,119,000, a 10% increase from $1,017,000 for the same period in 2024[45] - For the nine months ended February 28, 2025, consolidated net sales were approximately $4,562,000, compared to $4,299,000 for the same period in 2024, reflecting a 6% increase[45] - Total revenue for the three months ended February 28, 2025, was $1,119,000, an increase from $1,017,000 for the same period in 2024, representing a growth of approximately 10%[87] - North America generated $404,000 in revenue for the three months ended February 28, 2025, compared to $393,000 in 2024, reflecting a growth of about 2.8%[87] - Asia's revenue increased significantly to $365,000 in the three months ended February 28, 2025, from $210,000 in 2024, marking a growth of approximately 73.8%[87] Financial Position - As of February 28, 2025, the company had cash and cash equivalents of approximately $3,058,000 and an accumulated deficit of approximately $52 million[29] - As of February 28, 2025, total gross receivables were approximately $1,293,000, with key customers accounting for 76% of gross accounts receivable[46] - The Company had approximately $55,000 in advances from domestic customers as of February 28, 2025, representing prepayments on future shipments[70] - The Company has total minimum future lease payments of $569,000 as of February 28, 2025, with an imputed interest of $26,000[93] Operating Results - The company incurred net losses and negative cash flows from operations, indicating ongoing financial challenges[29] - Research and development costs were approximately $217,000 for the three months ended February 28, 2025, down from $343,000 for the same period in 2024[73] - Share-based compensation expenses related to stock options were approximately $91,000 for the three months ended February 28, 2025, compared to $340,000 for the same period in 2024[65] - Advertising costs were approximately $4,000 for the three months ended February 28, 2025, compared to $25,000 for the same period in 2024[76] Stock Transactions - The company sold 3,333,333 shares of common stock at a gross sales price of $2.40 per share, resulting in net proceeds of approximately $7,300,000 after deducting issuance fees[34] - During the nine months ended February 28, 2025, the company sold 3,525,359 shares at prices ranging from $0.36 to $1.04, generating net proceeds of approximately $2,015,000[37] - The Company sold 3,525,359 shares of common stock during the nine months ended February 28, 2025, resulting in gross proceeds of approximately $2,143,000[86] Asset Management - The Company invested approximately $165,000 into a privately held Polish distributor, owning about 6% of the investee[61] - The Company has established a reserve of approximately $25,000 for credit losses as of February 28, 2025[52] - Inventory reserves were approximately $422,000 as of February 28, 2025, down from $467,000 as of May 31, 2024[55] - As of February 28, 2025, the Company had approximately $475,000 of gross inventory located in Mexicali, Mexico[87] Lease Obligations - The total lease cost for the nine months ended February 28, 2025, was $280,000, slightly down from $283,000 in the same period of 2024[92] - Cash paid for operating lease liabilities was $274,000 for the nine months ended February 28, 2025, compared to $267,000 for the same period in 2024[93] - The weighted-average remaining lease term decreased to 1.06 years as of February 28, 2025, from 2.77 years in the previous year[93] - The Company operates a facility in Irvine, California, with a lease expiring in August 2026, and has the option to extend for an additional five years[89] Legal Matters - There were no material legal proceedings pending as of February 28, 2025, indicating a stable legal environment for the Company[95] Intangible Assets - The Company did not identify any indicators of impairment for intangible assets during the nine months ended February 28, 2025[60] - Amortization expense for intangible assets was approximately $5,000 for the three months ended February 28, 2025, compared to $4,000 for the same period in 2024[59] - The Company recognized a net operating loss that generated deferred tax assets for NOL carryforwards, establishing a full valuation allowance against these deferred tax assets as of February 28, 2025[74]

Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the EUFocus on Precision Medicine: Certification covers Biomerica's food intolerance products developed to support patients with Crohn's Disease and Ulcerative Colitis (UC), both of which are chronic and debilitating inflammatory bowel diseases (IBD).Global Reach: Positions Biomerica to expand its presence in the Europ ...

Core Points - Biomerica, Inc. has achieved CE-marking for its food intolerance products aimed at Crohn's Disease and Ulcerative Colitis under the EU's In Vitro Diagnostic Medical Devices Regulation (IVDR) [1][3][10] - This certification signifies Biomerica's commitment to expanding its international market presence and addresses the need for non-invasive therapies for chronic inflammatory bowel diseases [2][6][10] - The IVDR framework enhances the safety and performance of in-vitro diagnostics, and Biomerica's products have met the stringent requirements, facilitating easier market access in other regions [3][10] Product Details - Biomerica's food intolerance products utilize proprietary technology to identify dietary triggers that may cause inflammation in patients with Crohn's Disease and Ulcerative Colitis, offering a personalized management approach [4][5] - The products aim to improve patient quality of life by addressing specific food intolerances [4][5] Market Opportunity - The global market for treatments of Ulcerative Colitis is projected to grow from $7.72 billion in 2024 to $12.03 billion by 2032, with a compound annual growth rate (CAGR) of 5.7% [8] - The Crohn's Disease therapeutics market was estimated at $13.2 billion in 2023, indicating a significant demand for effective, non-invasive solutions [8] Company Strategy - With the IVDR certification, Biomerica is positioned to enhance its presence in the European in-vitro diagnostic market, aligning with its global growth strategy [6][10] - The company is focused on developing innovative diagnostic products that meet high technical standards and address unmet medical needs [5][10]

inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS)Research Finds Patients Following a Personalized Diet Therapy Created with inFoods® IBS, Experienced Reduced Abdominal Pain and Bloating IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdominal pain when ...